• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly May 2009

CenterWatch Monthly May 2009

May 1, 2009
CenterWatch Staff

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

Results of the CenterWatch 2009 Survey of Investigative Sites in the U.S. are in. For the second time in a row, U.S. sites have rated Novo Nordisk and Novartis the top one and two sponsors to work with, respectively. Eisai was ranked third by U.S. sites, a very high ranking considering that it is the first time that the company has elicited a significant response.

The total number of U.S. investigative sites responding to CenterWatch’s survey was 950, up nearly 50% the last time the survey was conducted two years ago. According to nearly half of responding sites, contract and budget negotiations are the factor that causes the most study delays.

CROs Going Private

Three large global CROs—Quintiles, PRA and PharmaNet—have gone private in recent years. Though each had company-specific reasons for the move, other large CROs may also want the freedom to pursue a long term strategic vision without worrying about the quarterly reporting demands of Wall Street.

Industry analysts believe that two or three small to mid-size public CROs that have weak financial results may consider going private in upcoming months, and a recent survey of public companies revealed that nearly one-quarter of respondents were considering going private due to corporate governance and disclosure reforms.

Inspection Programs Move from Retrospective to Risk-Based in Europe

Until the Clinical Trials Directive (2001/20/EC) went into effect five years ago, Good Clinical Practice (GCP) inspections were conducted retrospectively, often voluntarily and only with marketing authorization (MA) application. Now all 27 member states have at least one GCP inspector, and European Medicines Agency (EMEA) is using this collective body of expertise to widen the scope of inspections and push its prospective inspection program forward.

Eye On: Gastrointestinal Diseases

Gastrointestinal diseases may affect different sites in the entire digestive system from the mouth to the esophagus, stomach, small intestine, colon, rectum and anus. The liver, gallbladder and pancreas also secrete enzymes needed to break down and metabolize ingested food.

Symptoms of gastrointestinal disorders may include blood in the stool (melena or hematochezia), altered bowel habits, diarrhea or constipation, severe abdominal pain, unintentional weight loss and heartburn not responding to antacid treatment.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing